In addition, we found that percentage of area covered by COX2+ cells in TLO was significantly smaller in prostatectomy specimens from evanescent carcinoma patients (0.22 ± 0.07%), compared to areas occupied by COX2+ in prostate sections from PIN (0.73 ± 0.27%, p < 0.0001), intermediate (0.44 ± 0.24%, p = 0.0017) and advanced carcinoma patients (0.76 ± 0.18%, p < 0.0001) (Figure 6C). Here, PTGS2 is linked to carcinoma.